KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBT (2016 - 2025)

BeOne Medicines (ONC) has disclosed EBT for 11 consecutive years, with $243.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 384.9% to $243.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $510.8 million, a 195.83% increase, with the full-year FY2025 number at $459.4 million, up 186.19% from a year prior.
  • EBT was $243.2 million for Q4 2025 at BeOne Medicines, up from $147.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $243.2 million in Q4 2025 to a low of -$606.0 million in Q4 2021.
  • A 5-year average of -$213.3 million and a median of -$290.2 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 780.92% in 2022, then surged 384.9% in 2025.
  • BeOne Medicines' EBT stood at -$606.0 million in 2021, then increased by 28.89% to -$431.0 million in 2022, then increased by 18.61% to -$350.8 million in 2023, then skyrocketed by 75.67% to -$85.4 million in 2024, then soared by 384.9% to $243.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's EBT are $243.2 million (Q4 2025), $147.2 million (Q3 2025), and $99.5 million (Q2 2025).